1. Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI at Week 52 and Week 104*§¶. *n values shown in legend are the number of patients evaluable at Week 52. †A ≥5-point improvement from baseline in PCS and MCS scores was considered a clinically meaningful improvement. ‡The SF-36 score was based on imputed value by missing data (LOCF). §A change of −0.22 from baseline in HAQ-DI was considered a clinically meaningful improvement. ¶The HAQ-DI score was based on imputed value by missing data (LOCF).
Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI at Week 52 and Week 104*§¶. *n values shown in legend are the number of patients evaluable at Week 52. †A ≥5-point improvement from baseline in PCS and MCS scores was considered a clinically meaningful improvement. ‡The SF-36 score was based on imputed value by missing data (LOCF). §A change of −0.22 from baseline in HAQ-DI was considered a clinically meaningful improvement. ¶The HAQ-DI score was based on imputed value by missing data (LOCF). HAQ-DI, Health Assessment Questionnaire-Disability Index; LOCF, last observation carried forward; MCS, mental component summary; PCS, physical component summary; SF-36, 36-item Short Form Survey; Sir, sirukumab; q2w, every 2 weeks; q4w, every 4 weeks.
Carter Thorne et al. RMD Open 2018;4:e000731
Copyright © BMJ Publishing Group & EULAR. All rights reserved.